CEPH Message Board - Msg: 23192701

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: invbiotech	1/17/2007 1:02:15 PM
	of 998

Cephalon Upgrade By TSC Staff 1/16/2007 11:08 AM EST Shares of drugmaker Cephalon (CEPH - commentary - Cramer's Take - Rating) rose Tuesday after J.P. Morgan upgraded the stock to overweight from neutral on strong sales trends. "We believe CEPH shares deserve to trade at a premium," wrote J.P. Morgan health care analyst Adam Greene in a research report, saying the company's current valuation leaves room for upside. Shares rose 21 cents to $70.52. "While [epilepsy drug] Gabitril prescriptions have been in a free fall for nearly two years, prescriptions now appear to have stabilized," Greene says. "We expect the company to continue to take sizable price increases to offset some of the downward spiral." Since the beginning of 2005, Cephalon has increased its price on Gabitril three times, the analyst notes. J.P. Morgan Securities owns shares of Cephalon and makes a market in the stock. Cephalon is slated to report its fourth-quarter earnings on Feb. 14.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next